21st European Congress of Clinical Microbiology and Infectious Diseases

Activity of ceftaroline against European isolates from complicated skin and skin structure infections collected in 20082009

Abstract number: R2324

Morrissey I., Leakey A., Ambler J.

Objective: Ceftaroline (CPT) fosamil, the prodrug of the active compound CPT, is a broad-spectrum, parenteral cephalosporin recently approved in the USA for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. The aim of this study was to determine CPT activity against complicated skin and skin structure infection (cSSSI) isolates from Austria, Bulgaria, Czech Republic, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Russia, Slovakia, Spain, Switzerland, the Netherlands, Turkey and the UK.

Methods: 103 European centres submitted 2708 bacterial isolates causing cSSTIs in 2008–2009. These were re-identified and CPT (plus numerous comparator) MICs determined by CLSI broth microdilution at a central laboratory.

Results: Summary CPT MIC data are shown in the Table [cefuroxime (FUR) data are shown as a reference].

Conclusions: These data from a large collection of European isolates confirm the broad-spectrum activity of CPT against cSSSI pathogens. CPT is unique among clinically available cephalosporins, having good activity against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci, in addition to moderate activity against Gram-negative bacteria.